[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 351,790
  • Shares Outstanding, K 60,135
  • Annual Sales, $ 216,110 K
  • Annual Income, $ -220,470 K
  • EBIT $ -153 M
  • EBITDA $ -143 M
  • 60-Month Beta 0.60
  • Price/Sales 1.63
  • Price/Cash Flow N/A
  • Price/Book 1.25

Options Overview Details

View History
  • Implied Volatility 64.76% (-42.51%)
  • Historical Volatility 41.94%
  • IV Percentile 16%
  • IV Rank 12.14%
  • IV High 332.52% on 11/14/25
  • IV Low 27.75% on 09/04/25
  • Expected Move (DTE 36) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.36
  • Today's Volume 187
  • Volume Avg (30-Day) 275
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 9,940
  • Open Int (30-Day) 10,181
  • Expected Range 5.45 to 5.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 2
  • High Estimate $-0.49
  • Low Estimate $-0.52
  • Prior Year $-0.46
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.45 +0.09%
on 07/16/26
6.61 -17.61%
on 07/08/26
-0.28 (-4.89%)
since 06/16/26
3-Month
5.45 +0.09%
on 07/16/26
7.74 -29.54%
on 05/06/26
-1.71 (-23.88%)
since 04/16/26
52-Week
4.14 +31.64%
on 08/07/25
9.94 -45.17%
on 03/10/26
+0.64 (+13.31%)
since 07/16/25

Most Recent Stories

More News
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

WASHINGTON , July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA)...

VNDA : 5.45 (-6.84%)
NEREUSâ„¢ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

WASHINGTON , July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

WASHINGTON , July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind,...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

WASHINGTON , July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

WASHINGTON , May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

WASHINGTON , May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May...

VNDA : 5.45 (-6.84%)
Vanda: Q1 Earnings Snapshot

Vanda: Q1 Earnings Snapshot

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

WASHINGTON , May 6, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2026.

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals: Can Prescription Momentum Justify the Valuation Before Bysanti's Regulatory Verdict?

Barchart Research What to Expect from VNDA Earnings VNDA Generated May 5, 2026 Current Price $7.39 EPS Estimate $$-0.53 Consensus Rating Moderate Buy Average Move 7.71% Vanda Pharmaceuticals: Can Prescription...

VNDA : 5.45 (-6.84%)
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUSâ„¢ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

WASHINGTON , May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUSâ„¢ (tradipitant) is now commercially available across the United States for...

VNDA : 5.45 (-6.84%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 6.07
2nd Resistance Point 5.95
1st Resistance Point 5.70
Last Price 5.45
1st Support Level 5.32
2nd Support Level 5.20
3rd Support Level 4.95

See More

52-Week High 9.94
Fibonacci 61.8% 7.72
Fibonacci 50% 7.04
Fibonacci 38.2% 6.36
Last Price 5.45
52-Week Low 4.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.